Visual prognosis appears generally good after PPV for retained lens material

Article

An analysis of visual outcomes in a contemporary series of cataract surgery eyes that underwent pars plana vitrectomy (PPV) for retained lens material indicates these complicated cases tend to do well.

An analysis of visual outcomes in a contemporary series of cataract surgery eyes that underwent pars plana vitrectomy (PPV) for retained lens material indicates these complicated cases tend to do well, said Lawrence Y. Ho, MD.

Dr. Ho reported the findings from a retrospective review that included analyses for predictors of good and poor visual outcomes. The series included 166 consecutive cases from a 6-year period extending from January 2001 to January 2007. Follow-up exceeded 6 months in more than 80% of eyes. The visual results showed 72% of eyes achieved vision of 20/40 or better while only 10.8% ended up with vision of 20/200 or worse.

"The outcomes in this series surpass those in prior large series that showed only 58% of patients had vision of 20/40 or better while almost 18% saw 20/200 or worse. We believe improvements in both phaco technology and vitrectomy combined with earlier detection of treatment complications, such as CME with more widespread use of OCT, may account for the difference. However, this warrants further investigation," said Dr. Ho.

Predictors of vision outcomes were examined in a multivariate analysis. Better presenting vision, insertion of a posterior chamber IOL, and absence of preoperative eye disease were associated with a good vision outcome.

Development of glaucoma and presence of preexisting eye disease were associated with a poor vision outcome while anterior vitrectomy at the time of cataract surgery and sulcus lens placement at cataract surgery had protective value.

Recent Videos
David Yorston, FRCS, FRCOphth, discusses his EURETINA keynote lecture
Hoda Shamsnajafabadi, MSc, PhD, presents at the 2024 EURETINA meeting
Timothy L Jackson PhD, MB ChB, FRCOphth, speaks about a combination therapy for VEGF-A/C/D inhibition with sozinibercept and ranibizumab
Carl Awh, MD, FASRS, speaks about the American Society of Retina Specialists (ASRS) at EURETINA
Stefano Mercuri, MD, first author of the winning eposter “Genotype-phenotype correlations in a cohort of genetically determined Retinitis Pigmentosa (RP) Italian patients with Rho gene mutations”
Bahram Bodaghi, MD, PHD, FEBO at the 2024 EURETINA meeting
Enrico Borrelli, MD, FEBO, speaks at EURETINA
Aleksandra Rachitskaya, MD, FASRS, speaks about the Vit-Buckle Society at the 2024 EURETINA Congress.
© 2024 MJH Life Sciences

All rights reserved.